Protein biomarker detection in prostate cancer: A comprehensive review of electrochemical biosensors

IF 6.5 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Sensors and Actuators Reports Pub Date : 2023-06-26 DOI:10.1016/j.snr.2023.100168

Hashmatullah Nasimi , Jonna Skov Madsen , Ahmed H. Zedan , Anders Malmendal , Palle Jörn Sloth Osther , Fatima AlZahra'a Alatraktchi

{"title":"Protein biomarker detection in prostate cancer: A comprehensive review of electrochemical biosensors","authors":"Hashmatullah Nasimi , Jonna Skov Madsen , Ahmed H. Zedan , Anders Malmendal , Palle Jörn Sloth Osther , Fatima AlZahra'a Alatraktchi","doi":"10.1016/j.snr.2023.100168","DOIUrl":null,"url":null,"abstract":"<div><p>Rapid on-site electrochemical screening for prostate cancer (PCa) in the clinic holds the potential for early diagnosis of PCa patients. Currently, the accuracy of commonly used biomarkers is insufficient; however, several protein biomarker candidates show promise for diagnostic or prognostic patient screening. Among these candidates are Prostate specific antigen (PSA), Human glandular kallikrein 2 (hK2), Annexins 3 (Annex 3), Beta-2-microglobulin (β2M), Microseminoprotein-beta (MSMB), Serum amyloid A (SAA), and Engrailed-2 (EN2). This review provides an overview of the advancements in electrochemical biosensor development specifically targeting the detection of these seven biomarkers. The selection of these biomarkers was based on their suitability for protein-level detection using electrochemical sensors, as well as their presence in biological fluids. Moreover, we emphasize that relying solely on a single biomarker may not be sufficient to obtain precise diagnostic information. It is now widely accepted that panels of biomarkers measured in a multiplexed fashion are of greater clinical utility than single biomarkers. Therefore, we suggest that future research prioritize the utilization of multiplex electrochemical methods for measuring panels of protein biomarkers, offering a simple and efficient approach for regular PCa monitoring.</p></div>","PeriodicalId":426,"journal":{"name":"Sensors and Actuators Reports","volume":"6 ","pages":"Article 100168"},"PeriodicalIF":6.5000,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sensors and Actuators Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666053923000310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Rapid on-site electrochemical screening for prostate cancer (PCa) in the clinic holds the potential for early diagnosis of PCa patients. Currently, the accuracy of commonly used biomarkers is insufficient; however, several protein biomarker candidates show promise for diagnostic or prognostic patient screening. Among these candidates are Prostate specific antigen (PSA), Human glandular kallikrein 2 (hK2), Annexins 3 (Annex 3), Beta-2-microglobulin (β2M), Microseminoprotein-beta (MSMB), Serum amyloid A (SAA), and Engrailed-2 (EN2). This review provides an overview of the advancements in electrochemical biosensor development specifically targeting the detection of these seven biomarkers. The selection of these biomarkers was based on their suitability for protein-level detection using electrochemical sensors, as well as their presence in biological fluids. Moreover, we emphasize that relying solely on a single biomarker may not be sufficient to obtain precise diagnostic information. It is now widely accepted that panels of biomarkers measured in a multiplexed fashion are of greater clinical utility than single biomarkers. Therefore, we suggest that future research prioritize the utilization of multiplex electrochemical methods for measuring panels of protein biomarkers, offering a simple and efficient approach for regular PCa monitoring.

Abstract Image

查看原文本刊更多论文

前列腺癌蛋白质生物标志物检测:电化学生物传感器的综合综述

快速现场电化学筛查前列腺癌(PCa)在临床上具有早期诊断前列腺癌患者的潜力。目前，常用生物标志物的准确性不足;然而，一些候选蛋白质生物标志物显示出诊断或预后患者筛查的希望。这些候选药物包括前列腺特异性抗原(PSA)、人腺体钾化因子2 (hK2)、膜联蛋白3(附件3)、β -2微球蛋白(β2M)、微精原蛋白- β (MSMB)、血清淀粉样蛋白A (SAA)和EN2。本文综述了电化学生物传感器在检测这7种生物标志物方面的研究进展。这些生物标志物的选择是基于它们是否适合使用电化学传感器进行蛋白质水平检测，以及它们是否存在于生物流体中。此外，我们强调，仅仅依靠单一的生物标志物可能不足以获得准确的诊断信息。现在被广泛接受的是，以多种方式测量的生物标志物面板比单一生物标志物具有更大的临床效用。因此，我们建议未来的研究优先考虑利用多重电化学方法测量蛋白质生物标志物，为常规PCa监测提供一种简单有效的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Sensors and Actuators Reports Multiple-

CiteScore

9.60

自引率

0.00%

发文量

审稿时长

49 days

期刊介绍： Sensors and Actuators Reports is a peer-reviewed open access journal launched out from the Sensors and Actuators journal family. Sensors and Actuators Reports is dedicated to publishing new and original works in the field of all type of sensors and actuators, including bio-, chemical-, physical-, and nano- sensors and actuators, which demonstrates significant progress beyond the current state of the art. The journal regularly publishes original research papers, reviews, and short communications. For research papers and short communications, the journal aims to publish the new and original work supported by experimental results and as such purely theoretical works are not accepted.